ACADEMY OF MANAGED CARE PHARMACY for ACADEMY OF MANAGED CARE PHARMACY
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Support for increased FDA funding
| Lobbyist | Covered position, as disclosed |
|---|---|
| REGINIA GRAYSON BENJAMIN | — |
| ADAM PARKER NELSON | — |
Medicare/Medicaid MMM
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Senate Innovations Initiative
| Lobbyist | Covered position, as disclosed |
|---|---|
| REGINIA GRAYSON BENJAMIN | — |
| ADAM PARKER NELSON | — |
Pharmacy PHA
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, supporting the reauthorization of the National All Schedules Prescription Electronic Reporting Act (S 480/HR 1725)and providing comments to CDC on opioid dispensing guidelines
| Lobbyist | Covered position, as disclosed |
|---|---|
| REGINIA GRAYSON BENJAMIN | — |
| ADAM PARKER NELSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.